NCT03759158View on ClinicalTrials.gov

N-Acetyl Cysteine in the Prevention of Contrast Induced Nephropathy in Cirrhosis of Liver-NEPHRO Trial

NACompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

December 1, 2018

Primary Completion Date

January 15, 2019

Study Completion Date

January 15, 2019

Conditions
Liver Cirrhoses
Interventions
DRUG

N-Acetyl Cysteine

NAC 1200 mg twice daily one day prior to the procedure and on the day of the procedure.

DRUG

Placebo Oral Tablet

Placebo Oral Tablet twice daily.

Trial Locations (1)

110070

Institute of Liver and Biliary Sciences, New Delhi

All Listed Sponsors
lead

Institute of Liver and Biliary Sciences, India

OTHER

NCT03759158 - N-Acetyl Cysteine in the Prevention of Contrast Induced Nephropathy in Cirrhosis of Liver-NEPHRO Trial | Biotech Hunter | Biotech Hunter